Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)

0
1

Funding Opportunity ID:333378
Opportunity Number:RFA-DK-21-011
Opportunity Title:Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Grant
Category of Funding Activity:Food and Nutrition
Health
Category Explanation:
CFDA Number(s):93.847
Eligible Applicants:Small businesses
Additional Information on Eligibility:Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:May 06, 2021
Close Date:Oct 07, 2022
Last Updated Date:May 06, 2021
Award Ceiling:$0
Award Floor:$0
Estimated Total Program Funding:
Expected Number of Awards:
Description:This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies and their integration into open and closed loop hormone replacement systems.
Version:1





Visit the Official Webpage For More Details on Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)

LEAVE A REPLY

Please enter your comment!
Please enter your name here